CureVac’s Public Market Journey Nears Its Final Chapter

CureVac NL0015436031

The independent story of CureVac on the stock market is drawing to a definitive close. Following a successful takeover bid by rival BioNTech, the Tübingen-based biopharmaceutical firm has relinquished its autonomy. For remaining shareholders, the countdown has begun toward a mandatory delisting scheduled for January 2026.

Just prior to the acquisition's completion, CureVac released its financial figures for the third quarter of 2025. The report highlighted significant one-time effects:

• Revenue: €54.1 million
• Net Profit: €273.2 million
• Earnings Per Share: €1.21

The extraordinary net profit, which vastly exceeded quarterly revenue, stemmed from non-recurring accounting gains. A strategic realignment of licensing agreements, including those with GSK, generated substantial one-time income. These figures do not reflect ongoing operational performance but rather document the financial restructuring preceding the company's absorption.

BioNTech Assumes Commanding Control

The acceptance period for BioNTech's offer concluded on December 18 with a decisive outcome. Approximately 86.75% of all CureVac shares were tendered, granting BioNTech full control. The acquirer has already installed three of its own executives into CureVac's management team.

The next phase is clearly mapped out. A squeeze-out procedure is planned for January 2026 to acquire the remaining 13.25% of shares. Subsequently, the stock will be delisted from public exchanges, and the security identified by ISIN NL0015436031 will cease to be a tradable instrument.

Implications for Remaining Equity Holders

CureVac's share price now moves solely in relation to the valuation set by BioNTech's offer. Trading liquidity has diminished considerably, with institutional investors having largely exited their positions. In this context, traditional technical analysis or fresh analyst ratings have become irrelevant.

By early 2026, CureVac's tenure as a standalone listed entity will be permanently terminated. Its mRNA technology platform will then be fully integrated into the broader BioNTech corporation.